Loading…
Homeopathic Drug Product Safety, Quality, and Transparency Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2026 · third_quarter · Health Issues
Issues relating to the regulation of homeopathic medicine; H.R. 7050 / S.4692 - Homeopathic Drug Product Safety, Quality, and Transparency Act.
Client expense: Not reported · Firm income: $50,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Science/Technology
CFI's Office of Public Policy lobbied against S. 4692, the "Homeopathic Drug Product Safety, Quality, and Transparency Act." This legislation would allow lax federal regulation of the homeopathy industry, using homeopathy-specific standards set by the industry for safety and efficacy. While homeopathy groups favor this approach, evidence shows that these products are not safe for American consumers and patients. The Office of Public Policy continues to raise awareness among Congressional offices regarding this public health issue.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Issues relating to the regulation of homeopathic medicine; H.R. 7050 / S.4692 - Homeopathic Drug Product Safety, Quality, and Transparency Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Science/Technology
CFI's Office of Public Policy lobbied against S. 4692, the "Homeopathic Drug Product Safety, Quality, and Transparency Act." This legislation would allow lax federal regulation of the homeopathy industry, using homeopathy-specific standards set by the industry for safety and efficacy. While homeopathy groups favor this approach, evidence shows that these products are not safe for American consumers and patients. The Office of Public Policy continues to raise awareness among Congressional offices regarding this public health issue.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE